Dataset Information

Leptin-deficient Mouse Serum TMT-label Discovery Proteomics Profiling

ABSTRACT: The aim of this project was to profile the proteome of mouse-derived serum in order to identify those that showed significant quantitative different proteins among leptin-deficient (db/db) mouse, the genetic non-alcoholic fatty liver disease (NAFLD) mouse model and their lean bks mouse group.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Blood Serum

SUBMITTER: Yu Zhang

LAB HEAD: Suowen Xu

PROVIDER: PXD027937 | Pride | 2022-10-14

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 16

Publications

Comparative Proteomic Analysis of Liver Tissues and Serum in <i>db</i>/<i>db</i> Mice.

Zhang Yu Y Wu Xiumei X Xu Mengyun M Yue Tong T Ling Ping P Fang Tingyu T Luo Sihui S Xu Suowen S Weng Jianping J

International journal of molecular sciences 20220826 17

<h4>Background and aims</h4>Non-alcoholic fatty liver disease (NAFLD) affects one-quarter of individuals worldwide. Liver biopsy, as the current reliable method for NAFLD evaluation, causes low patient acceptance because of the nature of invasive sampling. Therefore, sensitive non-invasive serum biomarkers are urgently needed.<h4>Results</h4>The serum gene ontology (GO) classification and Kyoto encyclopedia of genes and genomes (KEGG) analysis revealed the DEPs enriched in pathways including JAK ...[more]

PMID: 36077090

Similar Datasets

Project description:Mesenchymal stem cell (MSC) therapy improves liver function in patients with liver cirrhosis. However, the therapeutic mechanism underlying MSC therapy remains unclear. Therefore, this study aimed to elucidate the therapeutic mechanism underlying MSC therapy by analyzing changes in the modification and expression of proteins 1-month post-treatment with MSCs. This prospective study included 11 patients with cirrhosis who received MSC injection in the First Hospital of Lanzhou University. The laboratory indexes before and after treatment were collected to evaluate the clinical treatment effect of MSCs, and peptide segments were extracted from liver tissue before and after treatment to revealed the protein expression and lactylation modification. Meanwhile, weighted gene co-expression network analysis was used to analyze co-expression protein modules and their relationship with clinical features. The patients with liver cirrhosis showed an improvement trend after receiving MSC treatment, specifically, the liver protein synthesis function was significantly improved and coagulation function was also significantly improved. Proteomics combined with lactic acid proteomics revealed 160 Lysine lactylation (Kla) sites of 119 proteins. The downregulated lactylated proteins were associated with metabolic processes. The upregulated lactylated proteins were involved in biological processes. The protein-based co-expression module was significantly related to alkaline phosphatase, total bilirubin (TBIL), indirect bilirubin (IBIL), direct bilirubin (DBIL), and ALB, and 10 proteins significantly related to ALB and 10 proteins significantly related to bilirubin were screened. The changes in clinical indexes before and after treatment indicate that the clinical effects of MSC treatment are related to cell metabolism. Overall, this study is the first study to comprehensively and systematically reveal the changes of lactylated proteins and expression after treatment with MSC by the self-control of patients, and lays a foundation for understanding the functions of lactylation modification in MSC therapy.

			Action	DRS
	Max-Quant-txt.zip	Other
	VA083TQ_1.raw	Raw
	VA083TQ_10.raw	Raw
	VA083TQ_11.raw	Raw
	VA083TQ_12.raw	Raw